Autonomix Medical, Inc.
Close on Oct 19, 2026
- Market cap
- $1.44M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Quarterly results announced on Form 8-K, Item 2.02
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q3 FY2025 Ended Dec 31, 2024 | Feb 13, 2025 | Before market open | – | – | – |
| Q2 FY2025 Ended Sep 30, 2024 | Nov 12, 2024 | Before market open | – | – | – |
| Q1 FY2025 Ended Jun 30, 2024 | Aug 13, 2024 | Before market open | – | – | – |
| Q4 FY2024 Ended Mar 31, 2024 | May 31, 2024 | After market close | – | – | – |
Press releases
Announcements Autonomix Medical filed with the SEC
Autonomix Medical Enters into $4.9 Million Warrant Inducement
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K
Autonomix Medical Enters into $2.6 Million Warrant Inducement Priced At-the-Market Under Nasdaq Rules
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K
Autonomix Announces Reverse Stock Split
Charter or bylaw amendment · Other events · EX-99.1 to Form 8-K
EX-99.2 to Form 8-K
Regulation FD disclosure · EX-99.2 to Form 8-K
Autonomix Medical, Inc. Exercise of Warrants for $2.5 Million Gross Proceeds
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K
EX-99.2 to Form 8-K
Regulation FD disclosure · EX-99.2 to Form 8-K
Item 7. Management ’ s Discussion and Analysis of Financial Conditions and Results of Operations.
Material agreement · Other events · EX-99.1 to Form 8-K
Autonomix Medical, Inc. Reports Third Quarter Fiscal Year 2025 Financial Results and Provides a Corporate Update
Results of operations · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
Autonomix Medical, Inc. Announces Pricing of $9.0 Million Underwritten Public Offering
Material agreement · Other events · EX-99.1 to Form 8-K
Autonomix Medical, Inc. Announces Closing of $10.0 Million Underwritten Public Offering Including Partial Exercise of Over-Allotment Option
Material agreement · Other events · EX-99.2 to Form 8-K
Autonomix Medical, Inc. Reports Second Quarter Fiscal Year 2025 Financial Results and Provides a Corporate Update
Results of operations · EX-99.1 to Form 8-K
Autonomix Announces Reverse Stock Split
Charter or bylaw amendment · Other events · EX-99.1 to Form 8-K
Autonomix Medical, Inc. Reports First Quarter Fiscal Year 2025 Financial Results and Reiterates Near-Term Milestones
Results of operations · EX-99.1 to Form 8-K
Autonomix Enters into Definitive Agreement to License Intellectual Property for FDA-Cleared Ablation Technology from RF Innovations, Inc.
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
Autonomix Announces Positive Topline Results from First Five Lead-In Patients in Ongoing Human Clinical Trial
Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.2 to Form 8-K
Regulation FD disclosure · EX-99.2 to Form 8-K
Autonomix Enhances Executive Leadership Team with Appointment of Proven Medical Technology Leader, Brad Hauser, as President and Chief Executive Officer
Unregistered share sale · Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
CONFIDENTIAL DRAFT NOT FOR IMMEDIATE RELEASE
Results of operations · EX-99.1 to Form 8-K
Breakthrough Technology That Could Transform Nerve - Targeted Treatments
Regulation FD disclosure · EX-99.1 to Form 8-K
Inc. Completes $8,000,000 Transaction for Exclusive Worldwide Rights to Technology for Cardiology Field Use – Over 100 patents
Unregistered share sale · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Inc. Announces Closing of $11.2 Million in Gross Proceeds from Initial Public Offering
Unregistered share sale · Regulation FD disclosure · Other events · EX-99.2 to Form 8-K